<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92516">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037854</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1324</org_study_id>
    <nct_id>NCT02037854</nct_id>
  </id_info>
  <brief_title>PEP-1324: Glycemic Response Testing</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <authority>Canada: WIRB</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether food ingredient(s) affect glycemic and
      insulinemic responses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Incremental area under the blood glucose response cruve</measure>
    <time_frame>0-2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>peak blood glucose</measure>
    <time_frame>0-2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak insulin</measure>
    <time_frame>0-2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Glycemic Response</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A nutrient formulation without the active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutrient formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutrient formulations with variable amounts of active ingredients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nutrient formulation</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Nutrient formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 18-75 years of age

          -  Subject is male or non-pregnant females, 18-75 years of age, inclusive

          -  Subject has a body mass index (BMI) ≥ 20.0 and &lt; 35 kg/m² at screening (visit 1).

          -  Subject has to be non-smoker.

          -  Subject is willing to maintain habitual diet, physical activity pattern, and body
             weight throughout the trial.

          -  Subject is willing to maintain current dietary supplement use throughout the trial.
             On test days, subject agrees not to take any dietary supplements until dismissal from
             the GI labs. Failure to comply will result in a rescheduled test visit.

          -  Subject has normal fasting serum glucose (&lt;7.0mmol/L capillary corresponding to whole
             blood glucose &lt;6.3mmol/L).

          -  Subject is willing to abstain from alcohol consumption and avoid vigorous physical
             activity for 24 h prior to all test visits.

          -  Subject has no health conditions that would prevent him from fulfilling the study
             requirements as judged by the Investigator on the basis of medical history.

          -  Subject understands the study procedures and signs forms providing informed consent
             to participate in the study and authorization for release of relevant protected
             health information to the study investigator.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janice Campbell</last_name>
    <email>JCampbell@gilabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GI Labs</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Campbell</last_name>
      <email>JCampbell@gilabs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
